Skip to content

The Efficacy of Friedrich's Ataxia Treatment Using Stem Cell Transplantation

Evaluation of the safety and efficacy of treatment for Friedreich's ataxia using stem cell transplatation in patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250503065580N1
Enrollment
5
Registered
2025-05-19
Start date
2025-06-05
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Friedreich's ataxia. Early-onset cerebellar ataxia

Interventions

Intervention group: Bone marrow samples (allogeneic) will be collected from five children with Friedrich's Ataxia, and the cells will be processed and cultured in the transplant environment. Subsequen

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 20 Years

Inclusion criteria

Inclusion criteria: Patients with Friedrich's Ataxia Having a positive genetic test with GAA repeat sequences

Exclusion criteria

Exclusion criteria: Individuals with seizures or epilepsy IQ below 80 Sensitivity to stem cell injection

Design outcomes

Primary

MeasureTime frame
Improvement in neurological function. Timepoint: 1, 2, 3, 4, 5, and 6 months after the first injection. Method of measurement: Regular neurological examinations are conducted (improvement in walking condition, increased pupillary response to light, partial improvement of eye nystagmus, improvement in speech, and improvement in hearing).

Secondary

MeasureTime frame
Safety of stem cell transplantation. Timepoint: 1, 2, 3, 4, 5, and 6 months after injection. Method of measurement: Assessment of response to stem cell transplantation through immune tolerance and absence of hypersensitivity reactions.;Tolerance of stem cell transplantation. Timepoint: 1, 2, 3, 4, 5, and 6 months after injection. Method of measurement: Assessment of response to stem cell transplantation through immune tolerance and absence of hypersensitivity reactions.;Improvement in cardiac function. Timepoint: 1, 2, 3, 4, 5, and 6 months after injection. Method of measurement: improvement in cardiac function using echocardiography.;Enhancement of quality of life. Timepoint: 1, 2, 3, 4, 5, and 6 months after injection. Method of measurement: Urinary and fecal continence, and self-care ability.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Khalesi

Mashhad University of Medical Sciences

khalesih4022@mums.ac.ir+98 51 3801 2503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026